Ann: Enrolment Completed in Australian Paediatric Clinical Study, page-75

Hi TT, re your comment "we would have to hand over the algorithm and the data to the China-based company. They would deploy to their own platform and pay us a per-use licence fee. It means handing over our IP. "

That may be right, but to me the point is, the risk of Chinese IP rip-off/violation potentially applies whether we enter the Chinese mkt or not. Partnering would speed up that potential. So we should enter the Chinese mkt regardless, to get the upside of population plus relatively high demand/head of population, given numbers of smokers and pollution.

However, I asked Tony (at a Sydney Techknow) how he would deal with this specific risk in China. His answer was that the plan is to partner with a Chinese health Co that is large enough to have the clout to take preventative action against other Chinese Cos that may try it on. That will hopefully prevent "Within 6 months every Chinese telehealth provider has a cough app".
Makes sense to me. I previously reported this at the time.